BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA)

August 12, 2025 5:04 AM EDT Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $44.00 price target on Oruka Therapeutics (NASDAQ: ORKA)The analyst comments "Recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login